UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


FORM 8-K


 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): Nobember 14, 2019

 

 


 

Cleveland BioLabs, Inc.

(Exact Name of Registrant as Specified in Charter)

 


 

 

DELAWARE

001-32954

20-0077155

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

 

73 High Street

Buffalo, NY 14203

 

(Address of Principal Executive Offices and zip code)

 

 

 

 

(716) 849-6810

 

(Registrant's Telephone Number, Including Area Code)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.005

CBLI

NASDAQ Capital Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                             

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 2.02 Results of Operations and Financial Conditions.

 

On November 14, 2019, Cleveland BioLabs, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2019. The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference.

 

Item 9.01 Financial Statements and Exhibits.

(d)

 

Exhibit  

No.

Description

99.1

Press Release titled “Cleveland BioLabs Reports Third Quarter 2019 Financial Results and Development Progress”, dated November 14, 2019

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Cleveland BioLabs, Inc.

 

 

 

 

 

Date: November 14, 2019

By: /s/ YAKOV KOGAN 

 

 

Name: Yakov Kogan

 

 

Title: Chief Executive Officer

 

 

Cleveland BioLabs (NASDAQ:CBLI)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Cleveland BioLabs Charts.
Cleveland BioLabs (NASDAQ:CBLI)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Cleveland BioLabs Charts.